GlaxoSmithKline Returns Drug Rights to ChemoCentryx After Failed Trial
ChemoCentryx now owns the drug's rights, including for inflammatory bowel disease, thus ending the seven-year strategic alliance between the two companies. GSK initially paid $63.5 million to ChemoCentryx to study treatments for IBD.
Vercirnon failed to meet GSK's primary and secondary endpoint in the first of four Phase III trials; the drug neither brought an improved clinical response nor clinical remission.
More Articles on Gastroenterology:
"S" or "C" Corporation for Your Gastroenterology Practice: Maximize Tax Deductions by Using Both!
Colonoscopy Could Prevent 40% Colon Cancer Cases, Study Says
Gastro Florida Practice Names Mark O'Neill as CEO
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- 7 Guidelines for Preparing a News Release About Surgery Center Accreditation
- Hiring Physicians: 6 Questions Providing Insight Into Candidates
- Physicians: Timeline for 2014 Deadlines to Remember
- Spotlight on MMX Healthcare: Developing Reliable, Affordable Tools for ASC Data Tracking & Management
- Hand Hygiene Story Roundup